|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|IPR||Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia|| |
(1 year, 3 months ago)
Crestor is owned by Ipr.
Crestor contains Rosuvastatin Calcium.
Crestor has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Crestor are:
Crestor was authorised for market use on 12 August, 2003.
Crestor is available in tablet;oral dosage forms.
The generics of Crestor are possible to be released after 27 May, 2023.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Orphan Drug Exclusivity (ODE)||May 27, 2023|
Market Authorisation Date: 12 August, 2003
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic